ITGA2B and COVID-19: In this context it is interesting that first clinical data on anti-platelet treatment using a GPIIb/IIIa antagonist (tirofiban) or other anti-platelet agents including a COX inhibitor (aspirin) or ADP receptor antagonist (clopidogrel) showed protective effects in severe COVID-19 (58, 59).